Search

Displaying results 3291 - 3300 of 10000 in total
  1. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. … TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system.

  2. Drug

    Brotizolam

    go.drugbank.com/drugs/DB09017
    ApprovedWithdrawn

    Brotizolam is an extremely potent drug and it is rapidly eliminated with an average half-life of 4.4 hours (range 3.6 - 7.9 hours). … Brotizolam is a sedative-hypnotic thienodiazepine drug which is a benzodiazepine analog. It demonstrates anxiolytic, anticonvulsant, hypnotic, sedative and skeletal muscle relaxant effects.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Efavirenz

    go.drugbank.com/drugs/DB00625
    ApprovedInvestigational

    a high risk for HIV transmission. … Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  4. Drug

    DDP733

    go.drugbank.com/drugs/DB05049
    Investigational

    DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD). … It is a partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system.

  5. Drug

    EDP1815

    go.drugbank.com/drugs/DB16486
    Investigational

    investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions such as

  6. Drug

    Quinine

    go.drugbank.com/drugs/DB00468
    ApprovedInvestigational

    It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. … An alkaloid derived from the bark of the cinchona tree.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  7. Drug

    Arecoline

    go.drugbank.com/drugs/DB04365
    Experimental

    It is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. It has been used as a euphoriant in the Pacific Islands. … An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors.

  8. Drug

    Dichloroacetic acid

    go.drugbank.com/drugs/DB08809
    ApprovedInvestigationalWithdrawn

    DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market … Salts of DCA are used as drugs since they inhibit the enzyme pyruvate dehydrogenase kinase.

  9. Drug

    ANA971

    go.drugbank.com/drugs/DB05127
    Experimental

    ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection. … ANA971 is a prodrug designed to improve the oral bioavailability of isatoribine.

  10. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure